We have used a series of in vitro and in vivo tests to assess the suitability of two new degradable polymers for application as coatings for drug-eluting stents. The first is a family of urethane-linked multi-block copolymers (MBCP) that comprise blocks of lactide, glycolide, ε-caprolactone and/or poly(ethylene glycol) chain-extended with 1,4-butanediisocyanate (SynBiosys™ polymers). The second is a family of maltodextrin (MD) modified with fatty acid sidechains to yield a hydrophobic polymer (Eureka™ SOLO polymers). We coated stainless-steel stents with two representative urethane-linked MBCPs and one hydrophobic MD polymer alone or in combination with the anti-restenotic drug sirolimus. Urethane-linked MBCPs formed uniform coatings on the stent substrates, withstood crimping and expansion on balloon catheters, completely released sirolimus from the coating within 30 days, and degraded within 30-60 days in PBS. The hydrophobic MD polymer formed uniform coatings, exhibited somewhat slower release of sirolimus (approx. 85% within 30 days), degraded within 60 days in PBS when sirolimus was incorporated in the coating, but showed very slow degradation in the absence of drug. We implanted stents coated with urethane-linked MBCPs or hydrophobic MD polymers in a porcine coronary artery model and used histological analysis at 28-and 90-day end-points to assess the biological response to the materials. Measures of stenosis and inflammation for urethane-linked MBCP and hydrophobic MD polymer coatings were not statistically different from bare metal controls at 28 and 90 days, suggesting that the polymers show good vascular biocompatibility. Endothelialization was nearly complete at 28 days and complete at 90 days for all formulations. Urethane-linked MBCP polymer-only and drug-eluting coatings and hydrophobic MD drug-eluting coatings were nearly completely degraded within 90 days in vivo whereas roughly half of hydrophobic MD polymer-only coatings remained after 90 days. Taken together, our in vitro and in vivo results suggest that SynBiosys urethane-linked MBCP and Eureka SOLO hydrophobic MD polymer families possess the phys- 
Introduction
Atherosclerosis -a major cause of heart disease characterized by a narrowing (stenosis) of the coronary arteries [1] [2] [3] [4] -is typically treated with percutaneous transluminal coronary angioplasty (PTCA), a minimally-invasive technique in which the stenosed artery is opened by means of a balloon inflated against the walls of the vessel [5, 6] . While PTCA effectively treats lesions and opens arteries, a significant fraction of treated arteries (30-40%) restenose within six months [3, 7] . The rate of stenosis is reduced to 15-20% when a permanent metallic stent is implanted at the site of PTCA [6, [8] [9] [10] . The advent of drug-eluting stents (DES), which deliver low doses of anti-restenotic drugs such as sirolimus (rapamycin), analogs of sirolimus, or paclitaxel locally at the lesion site, has reduced rates even further (to approx. 5%) [11] . There are currently four DES products on the market in the United States: Cypher ® Sirolimus-Eluting Coronary Stent (Cordis, Miami Lakes, FL, USA) [12] , Taxus ® Paclitaxel-Eluting Coronary Stent (Boston Scientific, Natick, MA, USA) [13] , Endeavor ® Zotarolimus-Eluting Coronary Stent (Medtronic, Minneapolis, MN, USA) [14] and XIENCE™ V Everolimus-Eluting Coronary Stent (Abbott Laboratories, Abbott Park, IL, USA) [15] . Each of these DES devices uses a similar approach: a drug is blended in a durable polymeric coating that is applied to the metal stent substrate. The polymer controls the release of the drug for approx. 30-60 days, thus administering the drug to the arterial tissue, suppressing the biological response to the injury caused by implantation of the stent, and reducing the incidence of restenosis. Beyond approx. 60 days, the rate of release of the drug is essentially zero, due either to complete elution of the drug from the coating (e.g., Cypher ® [16] ) or permanent entrapment of the drug within the coating (e.g., Taxus ® [17] ). The polymer -or the polymer and residual drug -remain on the stent for the duration of implant, well beyond the duration of their active function. An excellent review of these and other strategies for drug delivery from stents has been published by Acharya and Park [18] .
In the years since DES first appeared on the market, several reports claimed somewhat higher rates of late stent thrombosis for DES compared to their bare metal counterparts, particularly after anti-platelet therapies were discontinued [19] [20] [21] [22] [23] . One hypothesis that accounts for this apparent difference is that the cytotoxic (e.g., paclitaxel) and cytostatic (e.g., sirolimus and its analogs) compounds used in DES inhibit proper re-endothelialization of the stented artery segment and this delayed healing increases late thrombotic risks [19, 20] . A second hypothesis is that sensitivity to the durable polymer coatings present on the first-generation DES play a role in late stent thrombosis [19, 20] . In contrast to these earlier reports regarding DES safety, more recent analyses have shown that DES may, in fact, be associated with lower overall mortality than bare metal stents [24, 25] . Nonetheless, the early reports prompted research in the area of degradable polymers to use in place of durable polymers for DES coatings [18] . The concept of such an approach is that the polymer coating controls the release of anti-restenotic drugs and degrades completely, leaving a bare metal stent with a proven long-term biocompatibility and safety profile [26] . The duration of the drug-delivery phase is typically targeted to be 30-60 days [27] , since the inflammatory responses, cell migration, and proliferation processes following stent implantation typically occur within this timeframe [28] . Degradation of the polymer matrix may either occur in parallel to drug release or after completion of drug release. In the latter case, a gradual degradation is typically desired in order to avoid the inflammatory response caused by a bolus or accumulation of degradation products.
A number of commercial approaches to biodegradable DES coatings are in active development. The BioMatrix ® stent (Biosensors International Group, Singapore) has recently received CE Mark approval in Europe. The device comprises a stainless steel substrate, a non-degradable parylene tie layer, and an abluminal coating of a blend of poly(L-lactide) (PLLA) and Biolimus A9, a proprietary analog of sirolimus [29] . The PLLA coating of the BioMatrix ® stent degrades, but the stent that is left in the long-term is not truly bare metal due to the parylene tie layer that is bonded to the metal surface. The CoStar™ stent (Conor Medsystems, Menlo Park, CA, USA) forgoes a coating in favor of a myriad of small holes in the stent struts that serve as depots for drug delivery. Each hole is filled with, for example, a mixture of poly(lactide-co-glycolide) (PLGA) and paclitaxel and is layered in such a way to release the drug at the desired rate [30] . This strategy sidesteps issues related to coating adhesion during delivery of the stent, though it imposes other mechanical requirements on the polymer in order for each plug to remain intact [31] .
A wide variety of biodegradable polymers have been investigated for the application to DES as coatings or fully-degradable stents. Early work investigated PLLA, polyorthoesters, polycaprolactone, poly(ethylene oxide)/poly(butylene terepthalate) (PEO/PBTP), and poly(hydroxy butyrate)/valerate [32, 33] . More recently, tyrosine-based polycarbonates have been developed [34] and are under development as a fully-degradable stent (REVA Medical). Other polymers in development include coatings of poly(ester amides), which are based on amino acids and degrade by an enzymatic rather than hydrolytic mechanism [35] .
In this study, we have examined the suitability of two new families of degradable polymers for DES applications. The first is a urethane-linked multi-block co-polymer (SynBiosys™ from InnoCore Technologies and SurModics; hereafter 'urethane-linked MBCP') that comprises pre-polymer blocks of specific ratios of lactide, glycolide, ε-caprolactone and/or poly(ethylene glycol) (PEG) that are chain-extended with 1,4-butanediisocyanate, thereby forming a urethane linker moiety that is unique to this polymer family (Fig. 1A and 1B) [36, 37] . The multiblock architecture and composition of each block is designed to control the glass transition temperature (T g ), hydrophilicity/hydrophobicity, and degradation rate of the urethane-linked MBCPs. This, in turn, facilitates the tuning of the rate of elution of drugs from urethane-linked MBCP coatings. The multi-block co-polymer architecture permits adjustment of the degradation kinetics independent from the elution kinetics such that the polymer is completely resorbed shortly after complete elution of the drug load [38] . The lower glass transition temperature of urethane-linked MBCPs also facilitates the diffusion of degradation products from the polymer and limits the buildup of acidic degradation products in the polymer matrix that is typically associated with PLGA materials [39] .
The second family of polymers investigated in this study differs significantly in structure from polyesters (e.g., PLGA) commonly employed in degradable polymer applications. The polymer family (Eureka™ SOLO from SurModics; hereafter 'hydrophobic MD') comprises a maltodextrin (MD) backbone coupled to fatty acid sidechains that impart a hydrophobic nature to the polymer (Fig. 1C ) [40] [41] [42] . The products of degradation of hydrophobic MD polymers are initially a fatty acid (the hydrophobic sidechain) and a water-soluble polysaccharide, which further breaks down into glucose residues. This degradation scheme yields fewer acidic byproducts than standard PLGA materials. Consequently, we hypothesized that hydrophobic MD polymers would be well-tolerated in vivo.
We report here the results of a series of in vitro tests and of an in vivo porcine coronary artery implant study of stents coated with urethane-linked MBCPs and hydrophobic MD polymers. We assessed the mechanical properties, controlled release of sirolimus and degradation of representative members of urethane-linked MBCP and hydrophobic MD polymer families. We then performed histological analysis of stents coated with the polymers and explanted at 28-and 90-day end-points to determine the in vivo vascular biocompatibility profile of the two families of degradable polymers.
Materials and Methods

Materials
The polymers used for coatings in this study were synthesized and purified as described below. R Stents™ (316L stainless steel, 3.0 or 3.5 × 13 mm) and delivery catheters were purchased from OrbusNeich (Fort Lauderdale, FL, USA). Water was purified with a Barnstead system to a resistivity of 18.2 M ; other solvents were from Burdick & Jackson.
Polymer Synthesis
Urethane-Linked MBCPs
Prepolymer blocks and urethane-linked multi-block co-polymers were synthesized by methods reported in detail elsewhere [37] . Briefly, four different prepolymer blocks with accurately-controlled molecular weight were prepared by random ring-opening co-polymerization of glycolide (GA), ε-caprolactone (CL), and/or DL-lactide (LA) monomers using 1,4-butanediol or poly(ethylene glycol) (PEG) as an initiator and stannous octoate as a catalyst. Appropriate amounts of the resulting GALA, GACL, LA, and GAPEGCL prepolymers were then chain extended with 1,4-butanediisocyanate to obtain urethane-linked MCBPs (Fig. 1A and 1B) . The final polymers were purified by filtration, precipitation and drying. Two multiblock co-polymer compositions were included in this study: poly(glycolide-cocaprolactone)-block-poly(DL-lactide) ('GACL-LA') and poly(glycolide-co-PEGco-ε-caprolactone)-block-poly(glycolide-co-DL-lactide) ('GAPEGCL-GALA').
Hydrophobic MD Polymers
Maltodextrin was modified with hydrophobic groups as described in detail elsewhere [40, 41] . Briefly, dried maltodextrin was combined with 1-methylimidizole and an appropriate amount of long-chain anhydride to yield a polymer in which nearly all the hydroxyl groups of the maltodextrin were coupled to fatty acids (Fig. 1C) . The mixture was reacted at room temperature and the resulting material was precipitated in water, collected, and purified by filtration, precipitation and drying. A single polymer composition with fatty acid side-chains was included in this study, which we identify simply as 'hydrophobic MD'.
Stent Coating
Coating solutions were prepared by dissolving polymer in chloroform or tetrahydrofuran alone or in combination with a desired amount of sirolimus (2:1 (w/w) urethane-linked MBCP/sirolimus, 1:1 (w/w) hydrophobic MD/sirolimus). An ultrasonic spray process was used to prepare coatings of the polymers on OrbusNeich R Stent™ substrates. Excess solvent was removed from the coatings by first drying in a purged nitrogen environment followed by drying under vacuum overnight. Sirolimus loads were targeted to be at the high end of reported Cypher ® doses [16] ; actual loads of sirolimus in GACL-LA, GAPEGCL-GALA, and hydrophobic MD groups were 10.1 ± 0.7, 9.6 ± 1.5, and 15.9 ± 1.8 µg/mm, respectively. Stents for in vitro elution and degradation experiments were sterilized with ethylene oxide (EtO) and tested in the uncrimped state. Stents for implant or mechanical testing were mounted on balloon catheters at OrbusNeich prior to EtO sterilization.
In Vitro Tests
Mechanical Testing
Coated stents were mounted on balloon catheters and crimped in place at room temperature with an automated crimping tool. No sheath was used in the crimping process. After EtO sterilization, the stent/balloon assembly was immersed for 5 min in phosphate-buffered saline (PBS, 10 mM), pH 7.4 at 37 • C. A pressure of 10 atm was applied to the balloon in order to expand the stent, held for approx. 20 s, and then removed. Balloons and stents were examined with optical and scanning electron microscopy (SEM) to assess damage to the coating following the procedure. SEM images were obtained on a Leo Supra 40 VP (Carl Zeiss SMT, Peabody, MA, USA) with a field-emission source. Each experiment was performed in triplicate.
Elution of Sirolimus
Coated stents (uncrimped, unexpanded, sterilized with EtO) were placed in 3 ml PBS (pH 7.4) and incubated with light shaking at 37 • C. The concentration of sirolimus in the eluent at various intervals was quantified by UV absorbance at 279 nm (ε = 0.0491 ml · µg −1 · cm −1 ). The entire volume of buffer was refreshed after each reading. Coating formulations were tested in triplicate.
Degradation
Coated stents (uncrimped, unexpanded, sterilized with EtO) were placed in 1 ml PBS (pH 7.4) and incubated with light shaking at 37 • C. At intervals, stents were removed from the solution, rinsed briefly with water to remove salts, blotted dry, and allowed to dry further at ambient conditions for at least 2 h. Samples were then weighed and the weight was compared to initial coating weights to determine the amount of coating lost. After weighing, samples were returned to fresh PBS and the experiment continued. By this method, the mass loss of individual samples was tracked over time. Coating formulations were tested in triplicate.
In Vivo Testing and Assessment
The vascular biocompatibility of urethane-linked MBCPs and hydrophobic MD stent coatings was assessed in a porcine stent model as described by Schwartz and co-workers [26, 43] . Follow-up procedures were performed at 28 and 90 days.
Animal Care and Preparation
The animals used in the study were treated per the regulations of the USDA Animal Welfare Act and the conditions specified in The Guide for Care and Use of Laboratory Animals published by the NIH. The study protocol was reviewed and accepted by the Animal Research Committee at LyChron, LLC, where the study was performed. Thirty-six domestic Yorkshire crossbred swine (juveniles, age commensurate with 30 kg target weight) were treated with anti-platelet therapy comprising clopidogrel (75 mg p.o., QD) and aspirin (325 mg p.o., QD) daily, with the exception of the day of implant, beginning three days prior to the scheduled implant. On the day of the implant, animals were sedated, anesthetized and weighed. The femoral artery was accessed percutaneously, a 7F introducer arterial sheath was placed and advanced into the artery, and an initial bolus of heparin (100 IU/kg i.v.) was administered. Under fluoroscopic guidance, a 6F guide catheter was inserted through the sheath and advanced to the appropriate location. Angiographic images of vessels were obtained with contrast media and the proper location for stent deployment was determined by quantitative coronary angiography.
Stent Implantation
A total of 88 3.0/3.5 × 13 mm stents were implanted in the right coronary artery (RCA, n = 28), left anterior descending artery (LAD, n = 31) and left circumflex artery (LCX, n = 29) (one stent per artery in all cases). An effort was made to evenly distribute each experimental group and controls in the different vessels and to mix groups within a given animal, although variations in anatomy and limitations on the number of 3.5 mm stents prevented an ideal distribution of groups (Table 1) . A target segment ranging from mid-segment diameter of 2.6 mm to 3.4 mm was chosen, the stented balloon catheter was introduced, and pressure was applied to the balloon sufficient to reach a target balloon/artery ratio of 1.10:1 [26] . Actual ratios ranged from 1.03 to 1.38 (average 1.15 ± 0.05 for coronary arteries). The delivery system was removed, and a final angiogram obtained to determine device patency and additional acute deployment characteristics.
In addition, 24 3.0/3.5 × 13 mm stents were implanted in internal mammary arteries for evaluation of coating degradation. Stents were implanted by a procedure similar to that described above, though in these arteries a balloon/artery ratio of 1.20:1 was targeted to compensate for the more elastic nature of the internal mammary arteries.
Follow-up Procedure
ASA (325 mg/day PO) and clopidogrel (75 mg/day PO) were administered for the duration of the study starting the day following implant. Follow-up procedures were a Three stents from each coating treatment (those in the internal mammary arteries and up to one from the coronary arteries) were used to assess degradation. Histology was not performed on these samples.
performed at 28 or 90 days following implant. At the designated endpoint, animals were sedated and anesthetized and angiographic images of the stented arteries were recorded. Animals were killed and a necropsy was performed to assess gross appearance of the organs. The whole heart was excised, perfused with saline, and perfusion-fixed with 10% formalin. Arteries containing stents designated for assessment of coating degradation were dissected prior to fixation (see below).
Assessment of Degradation
In Vivo Stents used to assess coating degradation were implanted in the internal mammary arteries (n = 24) or one of the coronary arteries (n = 4). At each follow-up point, arteries containing stents for degradation analysis were dissected without fixation, rinsed with PBS, and held in PBS at 4 • C until the tissue was dissected from the stent. The arterial bed was dissected, the stent removed, and the neointimal tissue was removed from the stent with a scalpel, forceps and wooden mandrel. After tissue was removed, the coated stents were disinfected with 10% bleach, which was shown in separate experiments to have no significant effect on coating appearance. The coated area was determined by examining explanted stents with scanning electron microscopy (SEM) and qualitatively assessing the amount of coating remaining.
Histological Examination
Histological examination of stented coronary arteries was performed at CVPath Institute; histology was not performed on stented mammary arteries. Arteries were dehydrated in a graded series of ethanol and embedded in poly(methyl methacrylate). Sections (2-3 mm) were sawed from the proximal, middle and distal portions of each stent. Sections from the stents were cut on a rotary microtome to a thickness of 6 µm, mounted on charged glass slides, and stained with hematoxylin and eosin (H&E) or elastin-van Gieson-Trichrome (EVG). The non-stented proximal and distal sections of the artery were embedded in paraffin, sectioned to a thickness of 4-5 µm, and stained with H&E and Movat pentachrome. All sections were examined by light microscopy for the presence of inflammation, thrombus and neointimal formation and vessel wall injury. Morphometry software (IP Lab for Mac OS X, Scanalytics, Rockville, MD, USA) was calibrated at 1× objective using 2.0 mm linear and circular NIST traceable micrometers. Klarmann Rulings (Manchester, NH, USA) certified the micrometer graduations.
A vessel injury score was calculated according to the Schwartz method [43] . The cross-sectional areas (external elastic lamina (EEL), internal elastic lamina (IEL) and lumen) of each section were measured with digital morphometry. Neointimal thickness was measured as the distance from the inner surface of each stent strut to the luminal border. Area measurements were used to calculate vessel layer areas with the following formulas: Media = EEL − IEL; Neointima = IEL − Lumen; Stenosis (%) = 100 × (Neointimal area/IEL).
Ordinal data collected for each stent section included strut apposition to the vessel wall, fibrin deposition, granuloma reactions and hemorrhage around the stent struts. Values were expressed as a percentage of the total number of struts in each section. An overall neointimal inflammation and fibrin value was scored for each section (value 0-3) as described by Schwartz and co-workers [26] . Vessel sections showing two or more struts with granulomatous inflammation were scored with an inflammation value of 4. Adventitial inflammation was scored separately. Endothelial coverage was semi-quantified and expressed as the percentage of the lumen circumference covered by endothelium.
Statistical Analysis of Histological Data
Values are reported as mean plus-or-minus one standard deviation. The means of continuous variables (stenosis, endothelialization) for each stent group were compared using a one-way analysis of variance (ANOVA; JMP software, Cary, NC, USA). Statistical comparisons of individual group means were determined based on Tukey's HSD. For all parametric tests, a P -value of 0.05 or less was considered statistically significant. Stents with granulomas were excluded from statistical analysis (see Results and Discussion for further discussion and justification of this exclusion). Group means of semi-quantitative (ordinal) data (injury, inflammation, fibrin) were compared using the non-parametric Wilcoxon/Kruskal-Wallis (Rank Sums) test. If statistical significance was reached, a further sub-group analysis was performed comparing individual group means to the control bare metal stent. This analysis used a Bonferroni correction, where a more stringent P -value of 0.01 or less was considered statistically significant.
Assessment of Calcification
Analysis of histological sections revealed a material surrounding the struts that took up basic stain, which we hypothesized to be calcification. In order to identify this material, a series of tissue sections was stained with von Kossa to assess the presence of calcium in the tissue. Unstained sections were also prepared and observed without cover slips in an SEM. Elemental analysis was performed in the SEM with an X-ray detector (Oxford Instruments, Abingdon, UK) to identify the chemical nature of the basophilic material.
Results and Discussion
Mechanical Properties of Urethane-Linked MBCP and Hydrophobic MD Coatings
We used an ultrasonic spray-coating process to coat stainless steel stent substrates (3.0 × 13 mm) with urethane-linked MBCPs (GACL-LA with and without sirolimus, GAPEGCL-GALA with sirolimus) or hydrophobic MD (with and without sirolimus). All formulations formed uniform, clear, conformal coatings on the stent substrate.
In order to assess the mechanical properties of the polymer coatings, we subjected coated stents to a sequence of crimping onto a balloon catheter, soaking in PBS, and expansion via the balloon catheter that mimics the process of mounting, deployment, and implantation of the stent in a clinical application. None of the coatings exhibited significant damage from the crimping and expansion process (Fig. 2) . GACL-LA without drug showed a small tendency to form webs between struts and occasionally delaminate if struts touched one another during the crimping process (e.g., left side of Fig. 2A) . The presence of sirolimus in the coating appeared to reduce the tackiness of the coating, as neither of the urethane-linked MBCP formulations that contained sirolimus (33 wt%) showed signs of webbing or delamination ( Fig. 2B and 2C ). Hydrophobic MD coatings remained generally intact following balloon expansion (Fig. 2D ), but the coatings exhibited a tendency to crack and oc- casionally delaminate in regions that were in contact with the balloon (e.g., central area of Fig. 2D ). The presence of sirolimus did not appear to influence the performance of the hydrophobic MD coatings (Fig. 2E) . Such defects in hydrophobic MD coatings were not widespread and the coatings were considered acceptable for use in the in vivo portion of our study. However, we note that these results suggest that future efforts with hydrophobic MD formulations should focus on further reducing the occurrence of cracking and delamination of hydrophobic MD coatings.
In Vitro Elution of Sirolimus from Urethane-Linked MBCP and Hydrophobic MD Coatings
We used an in vitro method to assess the ability of urethane-linked MBCPs and hydrophobic MD coatings to control the release of sirolimus in PBS. Each of the coating formulations released the majority of their respective loads of sirolimus within 4 weeks (Fig. 3) . GACL-LA and GAPEGCL-GALA loaded with 33 wt% sirolimus exhibited release profiles similar to one another. Hydrophobic MD loaded with 50 wt% sirolimus showed a lower rate of release during approx. the first 5-10 days (Fig. 3, inset) , after which the rates of release were similar for all formulations.
The release rates reported here are likely on the fast end of rates that would be desirable for application to DES. We have previously evaluated other urethanelinked MBCPs and hydrophobic MD polymers and found that the complete release of sirolimus in PBS could be tuned from approx. 7 days to approx. 6 months, de- pending on the composition of the polymer [38, 42] . We selected the formulations for this study based in part on that previous work, which suggested that the specific formulations of polymer and drug chosen for this study would exhibit significant elution and degradation within the 90-day term of the in vivo portion of our evaluation (see detailed discussion below). In addition, the rapid release of sirolimus likely represents a worst-case scenario in terms of the biological impact of DES formulations of urethane-linked MBCPs and hydrophobic MD coatings.
In Vitro Degradation of Urethane-Linked MBCP and Hydrophobic MD Coatings
We evaluated the degradation of each of the coating formulations in a simple in vitro model. Coated stents were immersed in PBS at 37 • C and the mass of the coatings was monitored over time. All of the coating formulations, except hydrophobic MD without drug, completely degraded within 60 days in PBS (Fig. 4) . GAPEGCL-GALA/sirolimus degraded within approx. 21 days, whereas GACL-LA with or without sirolimus and hydrophobic MD/sirolimus degraded nearly completely within approx. 60 days.
The conditions used for this experiment clearly differ from those present in vivo, where, among other factors, fluid flow, enzymatic activity and cellular activity (macrophages, giant cells, leukocytes) may influence the degradation process. However, urethane-linked MBCPs and hydrophobic MD polymers degrade primarily by a hydrolytic mechanism, which makes PBS a reasonable approximation of the in vivo environment. The presence of sirolimus in the coatings appears to accelerate the degradation rate of hydrophobic MD coatings. Some of this acceleration is due to mass loss from the elution of sirolimus from the coating, but a simple comparison of the shape of the elution (Fig. 3) and degradation (Fig. 4) curves shows that the loss of coating mass is greater than the loss of drug mass during the course of elution (30 days). We hypothesize that this acceleration of polymer degradation is due to the creation of pathways for water penetration into the coating after the sirolimus, which comprises 50 wt% of the original coating, has eluted from the polymer.
The difference in degradation rates of polymer-only samples of hydrophobic MD and GACL-LA is likely attributable to the more hydrophobic (less hygroscopic) nature of hydrophobic MD polymers [44] . We have characterized the static contact angle of water on hydrophobic MD and urethane-linked MBCPs to be typically approx. 95 • and approx. 65 • , respectively (data not shown). Both families of polymers degrade primarily by hydrolysis of ester bonds, but the more hydrophobic nature of the modified MD polymer limits water penetration into the bulk of the coating and effectively limits degradation to the surface of the coating. In contrast, urethanelinked MBCPs take up some amount of water and degradation tends to proceed by hydrolysis of the polymer in the bulk, similar to other biodegradable aliphatic (co)polyesters, such as poly(DL-lactide) (PDLA) and poly(DL-lactide-co-gycolide) (PLGA) [45] .
We note that our in vitro elution and degradation experiments were conducted with stents that had been sterilized by EtO, but not crimped onto balloon catheters or expanded. We have previously observed that EtO sterilization tends to have a small but measureable effect on elution profiles of sirolimus from MBCPs or hydrophobic MD polymers, but that it typically has no effect on the degradation rate of these materials (unpublished results). We would expect that the crimping and expansion process would lead to somewhat faster elution and/or degradation rates for a given formulation than those reported here due to the strains placed on the coating during the expansion process. Preliminary data from our evaluation of urethane-linked MBCPs suggests that this hypothesis may be true for that family of polymers (unpublished results); we have not evaluated this effect on hydrophobic MD polymers. While we did not capture all aspects of sterilization and crimping effects on elution or degradation in this study, we note that, as part of any qualification for clinical use, the elution and degradation of ether-ester MBCPs and hydrophobic MD polymers should be evaluated on the specific stent of interest, with the desired drug and drug load, and after crimping and expansion (that is, in the form of a finished DES product) [46] .
In Vivo Degradation of Urethane-Linked MBCP and Hydrophobic MD Coatings
In an effort to better understand the rates of degradation of urethane-linked MBCPs and hydrophobic MD polymer coatings in vivo, we implanted coated stents in porcine internal mammary or coronary arteries and explanted the stents after 28 or 90 days (Table 1) . Upon explant, we dissected stented arteries (without fixation) and removed by hand the arterial and neointimal tissue from each stent. The process of removing the tissue caused deformation of the stent struts and distortion of the stent overall, but, remarkably, only minimal damage to the coating (e.g., occasional cuts through the coating from the scalpel, visible in the lower right portion of Fig. 5H ).
Since small amounts of residual tissue were often present on the stents after this process, we chose to assess the amount of coating remaining on the stents with scanning electron microscopy (SEM) rather than by gravimetric methods. We used SEM images to estimate the amount of the coating remaining on the stent at explant. While this method is only qualitative, it does facilitate comparison of the degradation among the coating formulations.
Regions of the stents that had coating remaining showed a darker appearance than uncoated areas in SEM images (Fig. 5) . The appearance of the stents indicated that coverage of all of the coating formulations decreased significantly within 90 days. Coatings of GACL-LA without drug and GAPEGCL-GALA/sirolimus were nearly completely absent from the stent surface at the 28-day explant ( Fig. 5A  and 5C ). Small amounts of coating and some residual tissue could be observed occasionally on the stents (e.g., the speckled appearance of Fig. 5F ). Coatings of GACL-LA/sirolimus and hydrophobic MD/sirolimus covered less than half of the stent area at 28 days (Fig. 5B and 5D ), but were mostly absent from the stents at the 90-day explant ( Fig. 5G and 5J ). Hydrophobic MD without drug showed widespread, though not complete, loss of coating coverage at 28 and 90 days.
We interpret the decrease in coating coverage over time as degradation of the polymers in the coatings, which we consider reasonable in light of the results of our in vitro degradation tests (above). We note, however, that the assessment of degradation by SEM estimations of coating loss cannot be used as an absolute assessment of the in vivo degradation of the coatings, since it does not take into account the possibility of coating fragments that might remain in the tissue. A more complete analysis could be performed by using histology or other methods to analyze for polymer fragments in the arterial tissue surrounding the stent.
The fact that the rates of degradation of the polymers observed in vivo were faster than the rate of degradation measured in vitro (PBS) suggests that biological processes and/or fluid flow (both absent in our in vitro tests) play important roles in the degradation process in vivo. This difference was most apparent for hydrophobic MD without drug, which showed essentially no mass loss in PBS over 60 days in vitro, but showed significant degradation within 90 days in vivo. We note that the coverage of the hydrophobic MD coating remained roughly constant between 28 and 90 days, but we were unable to quantify whether the total mass of coating changed during this time due to the presence of residual tissue on the stents. If degradation proceeds by a surface-mediated mechanism, we would expect to see little change in surface coverage as the polymer degraded, but a large decrease in the thickness of the coating and a corresponding decrease in coating mass. 
Biological Response to Urethane-Linked MBCPs and Hydrophobic MD Polymers: Histological Results
The primary goal of our porcine implant study was to assess the vascular biocompatibility of and local biological response to urethane-linked MBCP and hydrophobic MD stent coatings. To this end, we performed histological analysis of explanted arteries and compared bare metal stents (control) to stents coated with polymers with and without sirolimus. The formulations implanted in this study were selected because in vitro testing (above) suggested that elution and degradation of drugcontaining coatings would be complete within the 90-day term of the in vivo study. We note that the drug dose, release rate and degradation rate of the polymer formulations are meant to be representative and were not optimized prior to implant. Consequently, we intend this study to evaluate vascular biocompatibility but not pharmacokinetics or efficacy of urethane-linked MBCP and hydrophobic MD polymers.
General Observations
One premature death (of 36 total animals) occurred on day 8 of the study, the cause of which was a hemorrhage at the access site in the femoral artery and was not attributed to the presence of polymer-coated stents.
The implant characteristics of all stent groups were similar, which facilitates comparison of histological parameters among the groups. All stents showed good apposition to the arterial wall and lumens were patent with no evidence of thrombus formation, aneurysms, or malapposition at 28 and 90 days (see, for example, Fig. 6 ). Injury scores for all implants were minimal at 28 days (<0.4) and generally less than 1 at 90 days, except for those few stents with severe granulomas (see Schwartz and Edelman [26] for details of the scoring system used for injury and other observations). The low injury scores observed in this study are likely the result of the relatively small overstretch imposed on the arteries during stent implant (average overstretch ratio was 1.15 ± 0.05, whereas other studies have used ratios of 1.2-1.3 [43] ). When we analyzed individual stent data from our study, we observed a general increase in injury scores for samples with overstretch ratios of more than 1.2 at 28 days; we did not observe any trend at 90 days (data not shown).
We observed granulomas in seven stents (four animals) at the 28-day explant and four stents (three animals) at the 90-day explant. The granulomas were distributed among all coated stent groups but were not observed in the bare metal control group.
It is well accepted that granulomatous reactions around struts in porcine coronary stent implants occur at a higher rate than in other animal models (e.g., rabbits) or in humans. In our experience (CVPath Institute), granulomas are often observed in 50% or more of DES porcine coronary implants at 9 months. In the present study, granulomas were generally observed in DES and polymer-only coatings within the same animal, suggesting that the reaction was not based on drug alone or a specific polymer. The overall rate of granulomas in this study was 13.4%, comparable to other porcine studies [47] . Extensive granulomatous reactions cause excessive injury to surrounding tissues because the inflammatory reaction is often very robust and contains a variety of cells -such as macrophages, giant cells, T-lymphocytes and eosinophils -that are capable of secreting potent cytokines known to produce cell death [48] . Moreover, granulomas could lead to more tissue destruction based on the duration of the implant. For these reasons, we excluded stents with granulomas from subsequent analysis.
Stenosis
Area measurements (EEL, IEL and lumen) and calculated stenosis of each of the five different coating formulations showed no statistically-significant differences (P < 0.05) after 28 or 90 days of implant when compared to bare metal controls (Fig. 7A) . At 28 days, stenosis was statistically lower in groups that contained sirolimus when compared to companion polymer formulations without sirolimus (indicated by asterisks in Fig. 7A ). This result suggests an effect of the sirolimus (reducing tissue response to the injury of the implanted stent), though we emphasize that this difference was significant only between coated groups and not when compared to the bare metal control. At 90 days, statistical differences were observed only between GAPEGCL-GALA/sirolimus, which exhibited a higher level of stenosis, and GACL-LA/sirolimus or hydrophobic MD without drug; neither of these groups were statistically different form the bare metal control. We hypothesize that the higher level of stenosis observed in GAPEGCL-GALA/sirolimus at 90 days is due to the rapid elution and degradation of this material (see in vitro test- ing, above); the rapid release degradation products and short duration of sirolimus treatment likely minimized any benefit of the DES formulation in terms of reduction of neointimal growth beyond the first several weeks. This suggests that future formulations should seek slower degradation rates and a longer duration of drug release. The presence of granulomas did not generally lead to severely increased neointimal growth except in two stents from one animal at 28 days (GACL-LA/sirolimus and GAPEGCL-GALA/sirolimus), where the stenosis was greater than 90%. In sections from remaining stents with granulomas the percent stenosis was well below the mean values of control arteries (<15%).
Inflammatory Response
Intimal and adventitial inflammation was minimal in all groups at 28 days but generally higher at 90 days (Fig. 7B) . At 28 days, inflammation scores of all groups were not statistically different from the bare metal control, but inflammation scores of the hydrophobic MD group were statistically higher than GACL-LA/sirolimus, GAPEGCL-GALA/sirolimus, or hydrophobic MD/sirolimus (indicated by asterisks in Fig. 7B ). At 90 days, none of the treatment groups were significantly different from any of the other groups or controls. Giant cell infiltration around struts in all devices was very low (<5%), irrespective of polymer or drug at both time points. In rare instances, hemorrhage around stent struts was observed, although when present hemorrhage was mild. It was generally more prevalent in stents with biodegradable polymer alone (no drug) than in other groups.
The lack of statistical differences in inflammation scores of urethane-linked MBCPs or hydrophobic MD groups when compared to bare metal controls is particularly important in light of the evidence of complete or significant degradation of the polymers over the course of the implant. This suggests that neither the polymers nor the products of their degradation elicit any significant biological response. The primary degradation products of urethane-linked MBCPs are pyruvic acid (from lactide and glycolide), ω-hydroxyhexanoic acid (from ε-caprolactone) and PEG; small amounts of butanediamine (putrescine) and butanediol are also produced at the end of the degradation process [49, 50] . Hydrophobic MD likely degrades into fatty acids and glucose or oligosaccharides. The acidic degradation products of biodegradable orthopedic implants, such as bone screws or plates molded from PLLA-, PDLA-and PLGA-type polymers, often elicit inflammatory responses in vivo, which is attributed to a bolus of large amounts of acidic degradation products and the long-term presence of slowly degrading (crystalline) domains of the polymer [39] . The lack of a significant inflammatory response from the degradation products of the polymers in this study may be due to several factors: the relatively small amount of material (<1 mg) present in the stent coating; the fluid flow of the arterial environment, which acts to prevent buildup of degradation products in the site; the chemistry of the hydrophobic MD degradation products, which are not highly acidic; and/or the rubbery (T g < 37 • C) nature of urethane-linked MBCPs that permits gradual diffusion of acidic products out of the bulk of the polymer.
Fibrin Accumulation
We observed evidence of a biological effect of the sirolimus (delayed healing, as evidenced by the presence of fibrin) when we compared DES to polymer-only or bare metal stents (Fig. 7C) . At 28 days, accumulated fibrin around stent struts was typically mild to moderate in all groups that contained sirolimus, but the fibrin scores of these groups were statistically higher than the scores of polymer-only samples or bare metal controls (indicated by asterisks in Fig. 7C ). No statistical difference was observed between fibrin scores of polymer-only groups and bare metal controls. Accumulated fibrin was absent at 90 days, except in rare GACL-LA/sirolimus and hydrophobic MD/sirolimus stents where minimal fibrin was observed. The fibrin scores of all of the treatment and control groups were not statistically different from one another at 90 days.
Endothelialization
Despite the clear effect of sirolimus on the healing response in the artery, the luminal surfaces of all treatment groups were nearly completely endothelialized (Fig. 7D) , with only a few adherent platelets or inflammatory cells observed. At 28 days, GACL-LA/sirolimus showed a significantly lower level of endothelialization when compared to each of the other groups. None of the other treatment groups were statistically different from one another or the bare metal control. At 90 days, none of the groups showed any significant difference in the level of endothelialization when compared to any of the other groups.
Calcification Surrounding Struts
We noted the occasional presence of a material that took up basic stain around struts of samples coated with GAPEGCL-GALA/sirolimus at 28 days and a somewhat increased presence of this material in all groups except bare metal controls at 90 days. We hypothesized that this material, which took up basic (blue) stain in slices stained with H&E, was partially-degraded polymer or acidic polymer by-products. This seemed plausible in light of the fact that we observed more of the blue-stained material around struts coated with urethane-linked MBCPs, which have primarily acidic degradation products, than those coated with hydrophobic MD polymers, which have fewer acidic degradation products. However, von Kossa staining indicated that the material was a region of calcification and not polymer by-products (Fig. 8A) . We confirmed this with X-ray microanalysis, which revealed that the material was a calcium phosphate mineral ( Fig. 8B and 8C ). It is likely that the mineralized regions were the result of a small accumulation of acidic degradation products, which dropped the local pH and induced precipitation of calcium phosphate. While this phenomenon was easily observed in the healthy arteries used in this study, it is unlikely that this level of mineralization would be significant in clinical evaluations due to the extensive calcification typically present in diseased arteries. Notably, we observed no inflammatory response in the tissue surrounding the mineralized regions. The results of our in vivo evaluation provide good evidence of vascular biocompatibility of urethane-linked MBCPs and hydrophobic MD polymers. With one exception (endothelialization of GACL-LA/sirolimus at 28 days), none of the polymer or polymer/drug treatments showed significant differences in stenosis, inflammation, or endothelialization compared to bare metal controls. However, the findings of this study alone, while encouraging, are not sufficient to justify application of these materials in a clinical setting. We have initiated separate investigations of the biocompatibility of these polymers (ISO 10993 testing) in order to support future evaluations of the polymers in DES applications. Prior to any clinical investigation of urethane-linked MBCPs or hydrophobic MD polymers, extensive tests, including, for example, pharmacokinetics and preclinical efficacy, will need to be conducted on the specific combination of polymer, drug, drug load, and stent design desired in the final device [46] .
Conclusions
We used stainless steel stents as a substrate to test polymeric coatings prepared from two families of biodegradable polymers: urethane-linked ester-or ether-ester multi-block co-polymers and hydrophobically-modified maltodextrin. The results of our in vitro tests showed that DES coatings of urethane-linked MBCPs and hydrophobic MD polymers withstand the mechanical forces applied during crimping and stent deployment and exhibit minimal damage as a result of this process, elute sirolimus within approx. 30 days, and -with the exception of hydrophobic MD coating without sirolimus -degrade within approx. 60 days in PBS. All coating formulations, including hydrophobic MD without sirolimus, degraded significantly or completely within 90 days in vivo. Histological analysis of explanted stents showed no significant differences in the stenosis or inflammation scores of any of the polymer coating formulations when compared to bare metal controls at 28 or 90 days. Endothelialization was complete or nearly complete for all groups at 28 and 90 days. These results suggest that urethane-linked MBCPs and hydrophobic MD polymers exhibit mechanical properties, elution rates, degradation rates and biocompatibility profiles that make them suitable for next-generation drug-eluting stents.
